AlphAIAlphAI — Financial news for AI agents
timothysykes.comOCT 212 min read$CRL

Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype

Charles River Laboratories (CRL) shares rose 11.27% on strong earnings and growth outlook. The company reported $4.02B in annual revenue, $179.7M in operating cash flow, and guided for 5-7% organic revenue growth and 24% margins by 2030. Analysts raised price targets, with UBS upgrading to Buy and setting a $357 target.

Original reporting
timothysykes.com
Published Oct 21, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Charles River (CRL) Stock Charges Higher On Bullish Targets And AI Hype — source image
Source · timothysykes.com
Decision brief

The 30-second read

$CRLBullishHigh
01

Why it matters

Analyst upgrades and a UBS Buy rating are fresh, same‑day catalysts that have already moved the stock higher.

02

Market read

The upgrade-driven rally offers a short‑term buying opportunity for traders seeking momentum in biotech services.

03

What to watch

Potential regulatory scrutiny on AI‑driven drug discovery and execution risk of the $300M efficiency program.

Relevance 7/10Novelty 7/10Timing: today

Background

Charles River Laboratories reported strong earnings and an Investor Day that highlighted AI integration and cost‑saving initiatives, prompting analyst upgrades.

Company-level read

Ticker impact

$CRLBullishHigh confidence
Context

Analyst upgrades and higher price targets were issued today, driving an 11% intraday rally in Charles River Laboratories stock.

Expected impact

likely upward as traders price in higher targets and upgraded ratings

Evidence & confidence

Multiple major banks raised targets and UBS upgraded to Buy, providing fresh, time-sensitive catalyst.

Market effects

Sector

Positive sentiment may spill over to other CRO and biotech service providers.

Regional

U.S. biotech sector could see modest gains as investors rotate into CROs.

Global

Limited to U.S. and global pre‑clinical services market.

Counterpoint

What could challenge this read

The rally may be over‑extended; margins are still negative and cost‑saving execution risk remains.

Key entities

  • company
    Charles River Laboratories International Inc.

    U.S. contract research organization (CRO) whose stock surged on analyst upgrades.

  • financial_institution
    UBS

    Upgraded CRL to Buy and raised target to $357.

Read at source← All news

StoryCharles River Laboratories shares surge on strong earnings and analyst upgrades

Also covered by

2 outlets

Related articles

OCT 21
$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

stockstotrade.com3 min
OCT 21
$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

timothysykes.com3 min
SEP 24
$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

investing.com2 min
SEP 17
$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.

financialcontent.com2 min
SEP 15
$CRLMed

Charles River Laboratories at 2026 Global Healthcare Conference: growth builds

Charles River Laboratories (CRL) reported growth at the 2026 Global Healthcare Conference, with CEO Birgit Statham and CFO Glenn Sblendorio highlighting momentum in key segments. The company raised full-year organic growth and EPS guidance, citing stronger bookings in Discovery and Safety Assessment and improving margins in Manufacturing Support. Management also noted progress in stabilizing the non-human primate supply chain. However, they cautioned that recent strength may not sustain at the c

investing.com3 min